EnGeneIC_Logo.png
EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic
December 07, 2023 19:51 ET | EnGeneIC
EneneIC has been granted Fast Track designation for use of its novel Armed Nanocell Drug Conjugate (ANDC) in PDAC patients.
EnGeneIC_Logo.png
EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options
November 26, 2023 23:37 ET | EnGeneIC
SYDNEY and NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- EnGeneIC, a pioneer in personalised cancer therapeutics, announces the publication of its clinical trial results in peer reviewed prestigious...
PDAC logo (bilingual; with text)).jpg
PDAC announces 2024 Award Recipients
November 09, 2023 10:00 ET | Prospectors & Developers Association of Canada (PDAC)
2024 PDAC Award Recipients: Osisko Mining - Wabun Tribal Council - O3 Mining - Lundin Group - Victoria Gold Corp.
Vaccinex logo
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
October 31, 2023 09:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two...
BioNTech Expands Lat
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
October 19, 2023 06:45 ET | BioNTech SE
Initiation of Phase 2 builds on data from a Phase 1 clinical trial evaluating the safety and tolerability of autogene cevumeran (BNT122, RO7198457) in combination with the anti-PD-L1 immune checkpoint...
BioNTech erweitert f
BioNTech erweitert fortgeschrittenes klinisches Onkologie-Portfolio: Weiterer Phase-2-Studienstart mit mRNA-basierter individualisierter Neoantigen-spezifischer Immuntherapie in neuer Krebsindikation
October 19, 2023 06:45 ET | BioNTech SE
Grundlage für Phase-2-Studienstart waren Daten einer klinischen Phase-1-Studie zur Untersuchung der Sicherheit und Verträglichkeit von Autogene Cevumeran (BNT122, RO7198457) in Kombination mit...
Vaccinex logo
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
September 27, 2023 08:00 ET | Vaccinex, Inc.
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI's 20th Annual Discovery on...
PDAC logo (bilingual; with text)).jpg
Government’s Critical Minerals Strategy Recognizes Canada’s Once-in-a-Generation Opportunity to Lead Low Carbon Transition
December 09, 2022 13:30 ET | Prospectors & Developers Association of Canada (PDAC)
VANCOUVER, British Columbia, Dec. 09, 2022 (GLOBE NEWSWIRE) -- The Prospectors & Developers Association of Canada (PDAC) is encouraged to see its recommendations on behalf of Canada’s mineral...
Picture1.jpg
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
November 21, 2022 09:00 ET | Oncotelic Therapeutics, Inc.
R&D cost reduced in excess of 95% while continuing expansion of our OT-101 clinical programs through our joint ventureG&A cost reduced by approximately 50%Net loss reduced by approximately...
Picture1.jpg
Oncotelic Publishes SITC Meeting 2022 Presentation Materials
November 16, 2022 08:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...